Introduction
============

Leber hereditary optic neuropathy (LHON) was first reported in a patient more than 150 years ago, but it was first described (OMIM [535000](http://omim.org/entry/535000)) as a distinctive clinical entity in 1871 by the German ophthalmologist Theodore Leber (1840--1917) \[[@r1],[@r2]\]. The prevalence of LHON is estimated to be 1:50,000 and can occur at any age \[[@r3]\] with acute painless loss of central vision. LHON is bilateral in about 25% of cases and rarely unilateral \[[@r4]-[@r6]\]. If unilateral, the fellow eye is usually affected within 6--8 weeks. LHON is a maternally inherited disease and shows variable penetrance with a male preponderance of 86% \[[@r7]\]. LHON often progresses rapidly, which leads to severe visual loss with only little probability of visual recovery \[[@r8]\]. LHON is usually caused by mtDNA mutations residing in genes encoding subunits of complex I (component of mitochondrial respiratory chain). Ophthalmologic findings in LHON patients are variable, but classical LHON cases exhibit abnormalities like vascular tortuosity of the central retinal vessels, swelling of the retinal nerve fiber layer, a circumpapillary telangiectatic microangiopathy \[[@r9]\], and a cecocentral scotoma develops with variable preservation of peripheral vision. Early ophthalmologic changes can include hyperhemic optic discs, disc pseudoedema, and microangiopathy \[[@r10]\]. The disease finally leads to optic disc atrophy.

Nearly all patients worldwide carry one of three mtDNA pathogenic point mutations at positions NADH dehydrogenase subunit 4 (*ND4*):p.R340H, NADH dehydrogenase subunit 1 (*ND1*):p.A52T, and NADH dehydrogenase subunit 6 (*ND6*):p.M64V \[[@r8],[@r11]\]. Other pathogenic mtDNA LHON variants have also been described in various studies, with some still awaiting full confirmation for pathogenicity \[[@r9],[@r12]\], but mitochondrial NADH dehydrogenase subunit 1 (*MTND1*) and mitochondrial NADH dehydrogenase subunit 6 (*MTND6*) genes of mitochondria are thought to be "mutational hotspots" for LHON-causing mutations, in addition to primary LHON mutations \[[@r9],[@r13],[@r14]\]. Though there are several cases with primary LHON mutations, but in mitochondrial diseases the phenotype depends on various factors, such as threshold levels of wild-type mtDNA, tissue specific mosaicism, and mtDNA haplogroup. It has been shown that European mtDNA haplogroup J has genetic susceptibility to LHON \[[@r15]\], which suggests that certain alleles in certain haplogroups have deleterious or protective roles. Thus, each sequence variation needs to be studied or analyzed for the mtDNA background.

In the last two decades it has been shown that the primary mutations in complex I polypeptides lead to LHON, but this has not yet led to a satisfying explanation of the pathophysiological mechanisms; other mtDNA mutations may also lead to disease outbreak or modification of the phenotype in LHON patients. In this study we investigated patients presenting to ophthalmology clinic for subacute visual failure and suspected of having LHON. This study was planned with the aim to screen LHON cases for mtDNA sequence variations (PCR-DNA sequencing) and to assess how these variations can affect protein structure and function.

Methods
=======

Clinical examination and selection of cases
-------------------------------------------

Twenty clinically diagnosed LHON cases from northern India, presenting at Dr. Rajendra Prasad Centre for Ophthalmic Sciences (All India institute of medical Sciences, Ansari Nagar, New Delhi, India), were enrolled for this study after ethical approval from the institutional review board (IRB\#IRB00006862). Diagnosis of LHON is mainly based on the exclusion of all other factors responsible for sudden vision loss. So all those factors were considered and ruled out before a diagnosis of LHON was made. Detailed family history of the patients and controls was taken, which included associated periocular pain, to differentiate from papillitis; use of tobacco or alcohol or chronic systemic medication was noted to rule out toxic optic neuropathy. Detailed systemic and neurologic examination was done to check the involvement of cranial and peripheral nerves. Patients with LHON typically present with acute or subacute, sudden, painless, central vision loss leading to central scotoma and dyschromatopsia. All patients underwent a complete ophthalmic examination, including visual acuity measurement, slit lamp observation of the anterior segment, indirect ophthalmoscopy, and applanation tonometry. All patients also underwent an MRI of brain and orbit and fluorescein angiography.

No patient reported any drastic changes in their diet or intake of any drug or exposure to any toxic agent or pollutant around the time of visual loss. All patients had normal erythrocyte sedimentation rate and syphilis serology. None of the patients reported myotonia, exercise intolerance, palpitations, cardiac conduction abnormalities, oral or genital ulcers, erythema nodosum, or somatic anomalies. Patients were followed up in a neuro-ophthalmology clinic. Clinical manifestation of LHON patients have been tabulated ([Table 1](#t1){ref-type="table"}). A total of 20 ethnically and age-matched normal individuals without any history of ocular disorders were enrolled as controls. These were blood donors at AIIMS who reported no symptomatic metabolic, genetic, or ocular disorders as found on an extensive questionnaire regarding family history, past medical problems, and current health. The control group for mtDNA sequencing consisted of 20 individuals (15 men, mean age 23.64±2.54 years and five females, mean age 20.78±3.65 years).

###### Clinical phenotypes of LHON patients.

  **Patient ID**   **Age of onset (in years)**   **Sex**   **Neuro- Imaging**   **VA** **OD OS**   **Fundus findings OD OS**      **Fields**        
  ---------------- ----------------------------- --------- -------------------- ------------------ ------------------------------ ----------------- -----------------------
  LHON 1           22                            M         Normal               CF3ft CF5ft        diffuse disc pallor            Not possible      Not possible
  LHON 2           25                            M         Normal               20/80 20/50        diffuse disc pallor            central scotoma   central scotoma
  LHON 3           27                            M         Normal               CF5ft 20/60        diffuse disc pallor            Not possible      central scotoma
  LHON 4           24                            M         Normal               HMCF LP only       diffuse disc pallor            Not possible      Not possible
  LHON 5           18                            M         Normal               CF4ft CF5ft        diffuse disc pallor            Not possible      Not possible
  LHON 6           26                            M         Normal               20/200 20/100      diffuse disc pallor            central scotoma   central scotoma
  LHON 7           28                            M         Normal               CF5ft 20/60        temporal disc pallor           Not possible      central scotoma
  LHON 8           30                            M         Normal               20/80 20/50        diffuse disc pallor            central scotoma   central scotoma
  LHON 9           23                            M         Normal               20/200 20/100      diffuse disc pallor            central scotoma   central scotoma
  LHON 10          24                            M         Normal               CF1ft 20/100       diffuse disc pallor            Not possible      central scotoma
  LHON 11          29                            M         Normal               20/100 20/50       Severely diffuse disc pallor   central scotoma   central scotoma
  LHON 12          25                            M         Normal               20/80 20/50        diffuse disc pallor            central scotoma   central scotoma
  LHON 13          22                            F         Normal               20/200 20/100      diffuse disc pallor            Not possible      central scotoma
  LHON 14          20                            F         Normal               CF5ft 20/60        diffuse disc pallor            Not possible      central scotoma
  LHON 15          28                            M         Normal               20/200 20/100      diffuse disc pallor            central scotoma   central scotoma
  LHON 16          24                            M         Normal               20/100 20/50       Severely diffuse disc pallor   central scotoma   central scotoma
  LHON 17          13                            F         Normal               20/200 20/100      diffuse disc pallor            central scotoma   central scotoma
  LHON 18          21                            M         Normal               20/60 20/60        Severe diffuse disc pallor     central scotoma   central cecal scotoma
  LHON 19          11                            M         Normal               20/200 20/100      diffuse disc pallor            central scotoma   central scotoma
  LHON 20          29                            M         Normal               CF5ft 20/60        temporal disc pallor           Not possible      Not possible

Abbrevations: OD-right eye; OS-left eye; CF- Counting fingers; ft- distance in feet; HMCF- hand motions close to face; LP-Light perception; VA-Visual acuity.

Sample collection and DNA isolation
-----------------------------------

Five milliliters of peripheral blood were collected in EDTA vacutainer tubes after obtaining written consent and stored at −80 °C until further use. DNA was extracted from whole blood samples of all LHON patients and controls using a standard phenol chloroform method.

PCR amplification and sequence analysis of the mtDNA coding region
------------------------------------------------------------------

The entire coding region of the mtDNA was amplified in LHON patients and controls using 24 pairs of primers \[[@r16]\]. PCR amplifications for all primer sets were performed in a 30 μl volume containing 1.0 μl of 20 μM stock solution for each primer, 100 ng of genomic DNA, 1 unit of Taq polymerase (Banglore Genei, Karnataka, India), 0.1 mM of each dNTP, 4 μl of 10× PCR buffer (with 15 mM MgCl~2~), by means of 30 cycles of amplification, each consisting of 30 s denaturation at 94 °C, 30 s annealing at 56 °C, and 1 min extension at 72 °C. Finally, extension for 5 min at 72 °C was performed. Amplified PCR products were purified using a gel/PCR DNA fragment extraction kit (Geneaid Biotech Ltd., Sijhih City, Taiwan). Purified PCR products were sent for sequencing to Molecular Cloning Laboratories (South San Francisco, CA). The full mtDNA genome was sequenced except the D-loop as this is a hyper-variable region. All fragments were sequenced in both forward and reverse directions for confirmation of any nucleotide variation. All sequence variants from both LHON patients and controls were compared to the *Human Mitochondrial Reference Sequence* [NC_012920](http://www.ncbi.nlm.nih.gov/nuccore/NC_012920) provided by the NCBI, using [ClustalW2](http://www.ebi.ac.uk/Tools/msa/clustalw2/help/) (multiple sequence alignment program for DNA; European Molecular Biology Laboratory-European Bioinformatics Institute).

Computational assessment of missense mutations
----------------------------------------------

Two homology-based programs, Polymorphism Phenotyping ([PolyPhen](http://genetics.bwh.harvard.edu/pph/)) and Sorting Intolerant From Tolerant ([SIFT](http://sift.jcvi.org/)), were used to predict the functional impact of missense changes. [PolyPhen](http://genetics.bwh.harvard.edu/pph/) structurally analyzes an amino acid polymorphism and predicts whether that amino acid change is likely to be deleterious to protein function \[[@r17],[@r18]\]. [PolyPhen](http://genetics.bwh.harvard.edu/pph/) scores of \>2.0 suggest the polymorphism is probably damaging to protein function. Scores of 1.5--2.0 are possibly damaging, and scores of \<1.5 are likely benign. [SIFT](http://sift.jcvi.org/) is a sequence homology-based tool that sorts intolerant from tolerant amino acid substitutions and predicts whether an amino acid substitution in a protein will have a phenotypic effect \[[@r19]\]. [SIFT](http://sift.jcvi.org/) is based on the premise that protein evolution is correlated with protein function. Positions with normalized probabilities less than 0.05 are predicted to be deleterious and those greater than or equal to 0.05 are predicted to be tolerated by [SIFT](http://sift.jcvi.org/).

Comparative structure modeling
------------------------------

The knowledge of the three dimensional structure of the protein is essential to determine the implications of structural changes induced by mutations in the protein. When the precise structure for the protein is not available, the homologous protein with known structure (template) forms the essential prerequisite for developing the structural model for the protein employing comparative structure modeling approach. A [BLAST](http://blast.ncbi.nlm.nih.gov/Blast.cgi) search \[[@r20]\] was done to reveal the maximum sequence identity mitochondrial protein. A software package, [MODELER](http://salilab.org/modeller/) 9.2 program \[[@r21]\] in Discovery Studio (DS 2.0; Accelrys Inc., San Diego, CA), was used for molecular modeling and simulation. The best model in terms of stereochemistry, torsional geometry, and energetics parameters was selected for further analysis. The selected model was refined by energy minimization followed by molecular dynamics (MD) simulations.

The model structures of mutants were generated by altering the corresponding residues in the model structure of wild-type protein, using the "Build Mutant" protocol in DS 2.0. The generated model of the mutant was refined by energy minimization followed by MD simulations similar to the wild-type model.

Results
=======

Eleven patients were positive for one of the pathogenic changes whereas no pathogenic change was present in controls. MtDNA sequencing revealed a total of 47 nucleotide variations in 20 LHON patients, out of which 21.27% (10/47) variations were non synonymous and 78.72% (37/47) nucleotide changes were synonymous ([Table 2](#t2){ref-type="table"}). Also 29 nucleotide changes were found in 20 controls, out of which 17.24% (5/29) were non-synonymous and 82.75% (24/29) were found to be synonymous ([Table 3](#t3){ref-type="table"}). In patients highest number of changes were present in complex I genes (54%; 25/47) followed by complex III (19.14%; 9/47), complex IV (19.14%; 9/47), and then complex V (8.5%; 4/47). Although the frequency of non-synonymous variations found in controls were approximately similar to the patients but the changes in controls were non pathogenic. All the nucleotide variations were homoplasmic. No primary LHON mutation or pathogenic mutations were present in controls. Age of onset of symptoms did not differ significantly in patients with and without pathogenic mutations in current study.

###### Mitochondrial DNA sequence changes in LHON patients.

  **S. No.**   **Nucleotide substitution**   **Codon change**   **Amino acid change**   **Locus**   **Type of mutation**   **Polyphen/SIFT score**   **Pathogenicity**   **Reported/ Novel**
  ------------ ----------------------------- ------------------ ----------------------- ----------- ---------------------- ------------------------- ------------------- --------------------------------------------------------------------------------
  1\.          C3507G                        ACC\>ACG           p.T67T                  ND1         SYN                    NA                        NA                  mitomap
  2\.          C3741T                        ACC\>ACT           p.T145T                 ND1         SYN                    NA                        NA                  mitomap
  3\.          C3970T                        CTA\>TTA           p.L222L                 ND1         SYN                    NA                        NA                  [rs28357973](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=28357973)
  4\.          G4113A                        CTG\>CTA           p.L269L                 ND1         SYN                    NA                        NA                  mitomap
  5\.          \*G3460A                      GCC\>ACC           p.A52T                  ND1         NS                     1.646/0.00                YES                 mitomap
  6\.          T4703C                        AAT\>AAC           p.N78N                  ND2         SYN                    NA                        NA                  mitomap
  7\.          A4916G                        CTA\>CTG           p.L149L                 ND2         SYN                    NA                        NA                  mitomap
  8\.          A4944G                        ATC\>GTC           p.I159V                 ND2         NS                     0.468/0.29                No                  mitomap
  9\.          T5004C                        TTA\>CTA           p.L179L                 ND2         SYN                    NA                        NA                  [rs41419549](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=41419549)
  10\.         C6290T                        TAC\>TAT           p.Y129Y                 CO1         SYN                    NA                        NA                  mitomap
  11\.         G6305A                        GGG\>GGA           p.G134G                 CO1         SYN                    NA                        NA                  mtDB
  12\.         T6320C                        CCT\>CCC           p.P139P                 CO1         SYN                    NA                        NA                  mtDB
  13\.         G6734A                        ATG\>ATA           p.M277M                 CO1         SYN                    NA                        NA                  [rs41413745](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=41413745)
  14\.         T6908C                        TCT\>TCC           p.S335S                 CO1         SYN                    NA                        NA                  mtDB
  15\.         A7843G                        ATA\>ATG           p.M86M                  CO2         SYN                    NA                        NA                  mitomap
  16\.         T7961C                        TTA\>CTA           p.L126L                 CO2         SYN                    NA                        NA                  mitomap
  17\.         G8701A                        GCC\>ACC           p.A59T                  ATP6        NS                     0.430/0.60                NO                  [rs2000975](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2000975)
  18\.         G8865A                        GTG\>GTA           p.V113V                 ATP6        SYN                    NA                        NA                  mitomap
  19\.         G9123A                        CTG\>CTA           p.L199L                 ATP6        SYN                    NA                        NA                  [rs28358270](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=28358270)
  20\.         T9068C                        ATA\>ACA           p.M181T                 ATP6        NS                     1.579/0.00                YES                 mitomap
  21\.         C9540T                        CTA\>TTA           p.L112L                 CO3         SYN                    NA                        NA                  [rs2248727](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2248727)
  22\.         G9966A                        GTC\>ATC           p.V254I                 CO3         NS                     0.293/0.46                NO                  mitomap
  23\.         T10238C                       ATT\>ATC           p.I60I                  ND3         SYN                    NA                        NA                  [rs28358275](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=28358275)
  24\.         G10310A                       CTG\>CTA           p.T84T                  ND3         SYN                    NA                        NA                  [rs41467651](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=41467651)
  25\.         C10400T                       ACC\>ACT           p.T114T                 ND3         SYN                    NA                        NA                  [rs28358278](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=28358278)
  26\.         C10181T                       TTC\>TTT           p.F41F                  ND3         SYN                    NA                        NA                  mtDB
  27\.         G10589A                       CTG\>CTA           p.L40L                  ND4L        SYN                    NA                        NA                  [rs2853487](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2853487)
  28\.         \*G11778A                     CGC\>CAC           p.R340H                 ND4         NS                     2.608/0.00                YES                 mitomap
  29\.         C12348T                       CAC\>CAT           p.H4H                   ND5         SYN                    NA                        NA                  Novel
  30\.         T12477C                       AGT\>AGC           p.S47S                  ND5         SYN                    NA                        NA                  [rs28608480](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=28608480)
  31\.         A12810G                       TGA\>TGG           p.W158W                 ND5         SYN                    NA                        NA                  [rs28359174](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=28359174)
  32\.         A12849T                       GCA\>GCT           p.A171A                 ND5         SYN                    NA                        NA                  Novel
  33\.         T12879C                       GGT\>GGC           p.G181G                 ND5         SYN                    NA                        NA                  mitomap
  34\.         C12906T                       ATC\>ATT           p.I190I                 ND5         SYN                    NA                        NA                  Novel
  35\.         T13020C                       GGT\>GGC           p.G228G                 ND5         SYN                    NA                        NA                  [rs75577869](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=75577869)
  36\.         T13151C                       CTA\>CCA           p.L272P                 ND5         NS                     0.175/0.21                NO                  Novel
  37\.         T13281C                       GTT\>GTC           p.V315V                 ND5         SYN                    NA                        NA                  mtDB
  38\.         \*T14484C                     ATG\>ACG           p.M64V                  ND6         NS                     2.504/0.01                YES                 mitomap
  39\.         T14783C                       TTA\>CTA           p.L13L                  CYB         SYN                    NA                        NA                  mitomap
  40\.         C14950T                       CAC\>CAT           p.H68H                  CYB         SYN                    NA                        NA                  Novel
  41\.         G15043A                       GGG\>GGA           p.G99G                  CYB         SYN                    NA                        NA                  [rs28357684](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=28357684)
  42\.         A15061G                       GGA\>GGG           p.G105G                 CYB         SYN                    NA                        NA                  mitomap
  43\.         T15067C                       TTT\>TTC           p.F107F                 CYB         SYN                    NA                        NA                  mitomap
  44\.         T15097C                       ATT\>ATC           p.I117I                 CYB         SYN                    NA                        NA                  mtDB
  45\.         T15287C                       TTT\>CTT           p.F181L                 CYB         NS                     0.967/0.01                --                  mitomap
  46\.         G15110A                       GCA\>ACA           p.A122T                 CYB         NS                     0.401/0.65                NO                  [rs28357685](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=28357685)
  47\.         C15493T                       CTC\>CTT           p.L249L                 CYB         SYN                    NA                        NA                  mitomap

Abbreviations: \*Primary LHON mutations, NA- Not applicable, SYN synonymous; NS-non-synonymous; ND1-NADH dehydrogenase subunit 1; ND2-NADH dehydrogenase subunit 2; ND3-NADH dehydrogenase subunit 3; ND4-NADH dehydrogenase subunit 4; ND5-NADH dehydrogenase subunit 5; CO1-cytochrome c oxidase I; CO2-cytochrome c oxidase II; ATPase6-ATP synthase subunit a (F-ATPase protein 6); ATPase8-ATP synthase protein 8; CYB-cytochrome B.

###### MtDNA variations identified in controls. Polyphen and SIFT were used to predict the pathogenicity of non-synonymous changes.

  **S. No.**   **Nucleotide substitution**   **Codon Change**   **Amino acid change**   **Locus**   **Type of Mutation**   **PolyPhen/SIFT score**   **Pathogenecity**   **Reported/ Novel**
  ------------ ----------------------------- ------------------ ----------------------- ----------- ---------------------- ------------------------- ------------------- ---------------------
  1\.          G3591A                        CTG\>CTA           p.T95T                  ND1         SYN                    NA                        NA                  mtDB
  2\.          C3780T                        GGC\>GGT           p.G158G                 ND1         SYN                    NA                        NA                  mitomap
  3\.          G3918A                        GAG\>GAA           p.E204E                 ND1         SYN                    NA                        NA                  mtDB
  4\.          A3933G                        TCA\>TCG           p.S209S                 ND1         SYN                    NA                        NA                  mitomap
  5\.          A4093G                        ACC\>GCC           p.T263A                 ND1         NS                     0.476/0.38                No                  mtDB
  6\.          A4793G                        ATA\>ATG           p.M108M                 ND2         SYN                    NA                        NA                  mtDB
  7\.          A5351G                        CTA\>CTG           p.L294L                 ND2         SYN                    NA                        NA                  mtDB
  8\.          G6305A                        GGG\>GGA           p.G134G                 CO1         SYN                    NA                        NA                  mtDB
  9\.          G6962A                        CTG\>CTA           p.T353T                 CO1         SYN                    NA                        NA                  mtDB
  10\.         T7738C                        ACT\>ACC           p.T51T                  CO2         SYN                    NA                        NA                  mtDB
  11\.         G7762A                        CAG\>CAA           p.Q59Q                  CO2         SYN                    NA                        NA                  mtDB
  12\.         T8143C                        GCT\>GCC           p.A186A                 CO2         SYN                    NA                        NA                  mitomap
  13\.         G8251A                        GGG\>GGA           p.G222G                 CO2         SYN                    NA                        NA                  mtDB
  14\.         T8503G                        AAT\>AAG           p.N46K                  ATP8        NS                     0.090/1.00                No                  mtDB
  15\.         G8584A                        GCA\>ACA           p.A20T                  ATP6        NS                     0.362/0.19                No                  mtDB
  16\.         C8650T                        CTA\>TTA           p.L42L                  ATP6        SYN                    NA                        NA                  mtDB
  17\.         A8718G                        AAA\>AAG           p.K64K                  ATP6        SYN                    NA                        NA                  mtDB
  18\.         G8886A                        AAG\>AAA           p.K120K                 ATP6        SYN                    NA                        NA                  mitomap
  19\.         G10310A                       CTG\>CTA           p.T84T                  ND3         SYN                    NA                        NA                  mtDB
  20\.         T10873C                       CCT\>CCC           p.P48P                  ND4         SYN                    NA                        NA                  mtDB
  21\.         A11467G                       TTA\>TTG           p.L236L                 ND4         SYN                    NA                        NA                  mitomap
  22\.         G12372A                       CTG\>CTA           p.T12T                  ND5         SYN                    NA                        NA                  mtDB
  23\.         A12381G                       CTA\>CTG           p.L15L                  ND5         SYN                    NA                        NA                  mtDB
  24\.         G12406A                       GTT\>ATT           p.V24I                  ND5         NS                     0.299/0.72                No                  mtDB
  25\.         C12498T                       TTC\>TTT           p.F54F                  ND5         SYN                    NA                        NA                  mitomap
  26\.         G12561A                       CAG\>CAA           p.Q75Q                  ND5         SYN                    NA                        NA                  mtDB
  27\.         G13204A                       GTC\>ATC           p.V290I                 ND5         NS                     0.710/1.00                No                  mitomap
  28\.         G15172A                       GGG\>GGA           p.G142G                 CYB         SYN                    NA                        NA                  mtDB
  29\.         T15067C                       TTT\>TTC           p.F107F                 CYB         SYN                    NA                        NA                  mitomap

Abbreviations: SYN-synonymous; NS-non-synonymous; ND1-NADH dehydrogenase subunit 1; NA- Not applicable; ND2-NADH dehydrogenase subunit 2; ND3-NADH dehydrogenase subunit 3; ND4-NADH dehydrogenase subunit 4; ND5-NADH dehydrogenase subunit 5; CO1-cytochrome c oxidase I; CO2-cytochrome c oxidase II; ATPase6-ATP synthase subunit a (F-ATPase protein 6); ATPase8-ATP synthase protein 8; CYB-cytochrome B.

SIFT and PolyPhen analysis
--------------------------

[SIFT](http://sift.jcvi.org/) and [PolyPhen](http://genetics.bwh.harvard.edu/pph/) analysis of all nonsynonymous changes from cases and controls revealed five pathogenic changes, including primary LHON mutations (p.A52T in ND1 protein; p.M64V in ND6; p.M181T in adenosine triphosphate (ATP) synthase subunit a (F-ATPase protein 6) \[ATPase6\]; p.R340H in ND4, and p.F181L in cytochrome B (CYB) protein; [Table 2](#t2){ref-type="table"} and [Table 3](#t3){ref-type="table"}). Eleven patients were positive for either of these pathologic mtDNA nucleotide changes, but none of control harbored any pathogenic nucleotide change ([Table 3](#t3){ref-type="table"}).

Discussion
==========

This study enrolled 20 LHON patients who experienced acute or subacute, bilateral, persistent optic neuropathies characterized by central visual loss that occurred simultaneously or sequentially within a period of 1 year. In this study we report 54% variations in complex I (NADH dehydrogenase \[ND\] group of genes) of the electron transport chain (ETC) as found in earlier studies, which is approximately 50%--90% of LHON cases in different ethnic populations \[[@r22],[@r23]\]. Primary LHON mutations have been considered a hallmark of LHON patients \[[@r24],[@r25]\]. *ND1*:p.A52T mutation was present in two patients, *ND4*:p.R340H was present in six patients, and *ND6*:p.M64V was present in three patients. None of the patients with primary LHON mutations reported a multigenerational history compatible with maternal inheritance. Two patients had pathogenic mtDNA sequence changes (*ATP6*: p.M181T; *CYB*: p.F181L) other than primary LHON mutations, while others had no nonsynonymous mtDNA changes. In this study we found a greater number of synonymous changes in patients as compared to controls. Synonymous changes are often assumed to have no effect on protein structure and function. Studies have suggested that codon bias may be a mechanism of regulating gene expression levels \[[@r26]\]. The high number of synonymous changes may decrease the overall rate of translation as the choice of codon or which codon is preferred depends on which codon is translated more rapidly, timely, and effortlessly. Thus, a large number of synonymous variations may not alter amino acids due to degeneracy of code; however, it may affect the efficiency of translation machinery and thus may decrease the rate of ATP production.

Patients with no obvious mtDNA abnormalities might have no mitochondrial disease or they might have mtDNA abnormalities isolated to the optic nerve (tissue-specific mosaicism), conceptually similar to mitochondrial myopathies \[[@r27]\]. The other reason for this might be that the levels of mutant mtDNA are so low that it is not confirmed using PCR. However, these patients may have elevated oxidative stress comparable to patients with primary LHON mutations. The penetrance of optic neuropathies is incomplete, and males are affected five times more than females. Thus, it is believed that although mtDNA is the primary risk factor, there are other secondary factors that attribute to visual loss. Seventy-five percent of 14484 LHON pedigrees belong to European haplogroup J, and penetrance of optic neuropathy is increased by haplogroup-associated polymorphism. There is also increased penetrance of 11778 when it is in haplogroup J, but penetrance in the case of 3460 is not influenced by the mtDNA haplogroup. Only about one-third of individuals harboring one of these three mutations eventually develop LHON, and the penetrance varies among different families \[[@r28],[@r29]\]. Therefore, identification of other factors affecting LHON penetrance would be of value in elucidating the pathophysiology of retinal neuron loss, as well as in searching for clues that might relieve visual loss or prevent the onset of LHON.

Comparative structure modeling was done for two nonsysnonymous changes (*ATP6*: p.M181T; *CYB*: p.F181L) as the other nonsynonymous changes were found to be nonpathogenic on insilico analysis ([SIFT](http://sift.jcvi.org/) and [PolyPhen](http://genetics.bwh.harvard.edu/pph/)). Nonsynonymous nucleotide changes in *CYB* and *ATPase6* gene in LHON have been described previously \[[@r30]\]. Mutations in *ATPase6* have been reported in various diseases, like primary congenital glaucoma \[[@r31]\], primary open angle glaucoma, neuropathy--ataxia--retinitis pigmentosa, and mtDNA-associated Leigh syndrome patients \[[@r31],[@r32]\].

Mitochondrially encoded ATP synthase 6 is a subunit of the F~0~ complex of transmembrane F-type ATP synthase. ATP synthase comprises a rotary catalytic portion, F~1~-ATPase whose structure has been solved \[[@r33]\], a transmembrane portion F~0~, and two stalks that link F~1~ and F~0~. Two of the subunits of the F~0~ portion of ATP synthase, subunits 6 and 8 (or subunit a and A6L), are encoded in mtDNA in all animal cells \[[@r34]\]. This subunit (F~0~) is a key component of the proton channel and may play a direct role in the translocation of protons across the membrane \[[@r35]\]. The protein corresponds to ATP6 in the wild-type human mitochondria and consists of four helices and four connecting loops ([Figure 1](#f1){ref-type="fig"}). The mutation Met181Thr is present in the helix of the protein, which is part of the binding pocket ([Figure 2](#f2){ref-type="fig"}). The mutation replaces the Met residue, which is more hydrophobic compared to Thr and is also capable of making stacking interactions with neighboring residues. The Thr residue in the mutated protein is less hydrophobic than Met, the overall conformation of wild-type and mutant has changed due to the alteration of interactions with the neighboring amino acid residue Ser176 and Ile95 ([Figure 2](#f2){ref-type="fig"} and [Figure 3](#f3){ref-type="fig"}). Since the Phe residue possesses a longer aromatic side chain, the Arg177 side chain shifts away from it to minimize steric hindrance and interacts with Ile164. The point mutation Met181Thr induces a conformational change in the Ser176 and Ile95 side chain orientation and positions it to interact with other neighbor residues ([Figure 3](#f3){ref-type="fig"}). Since this mutation lies in the helix, it may affect its capability to interact with other subunit proteins of F~0~ assembly, which may lead to dysfunction of ATP synthase.

![Superimposed structure of wild-type and mutant human mitochondrial ATP synthase subunit a (F-ATPase protein 6) (ATP6) in a ribbon. The side chain of Met181 is shown as a ball and stick.](mv-v18-2687-f1){#f1}

![Surface structure of wild-type (green) and mutant (cyan) human mitochondrial ATP synthase subunit a (F-ATPase protein 6) (ATP6). Changes in M181T caused the changes in the surface cavity (shown by circles).](mv-v18-2687-f2){#f2}

![Model of wild-type human mitochondrial ATP synthase subunit a (F-ATPase protein 6) (ATP6) (green) superimposed on a model of M181T mutant (cyan). The side chain conformation of Met181, Ser176, and Ile95 (green) in the wild-type and Thr181, Ser176, and Ile95 (cyan) in the mutant are represented with the balls and sticks. The conformation of Thr181, Ser176, and Ile95 side chains were different in the native and mutant protein.](mv-v18-2687-f3){#f3}

Cytochrome bc1 (CYB) is a multisubunit membrane protein that has 11 subunits comprising three redox proteins: cytochrome b with two heme groups, cytochrome c1 possessing a covalently bound heme, and the iron-sulfur-containing protein with a \[Fe~2~S~2~\] cluster. The function of the other eight subunits in the mitochondrial protein is largely unclear. The CYB protein corresponds to cytochrome b in the wild-type human mitochondrial cytochrome bc1, which consists of 14 helices, two anti-parallel β-strands, and connecting loops ([Figure 4](#f4){ref-type="fig"}). We found a mutation of Phe to Leu at position 181, which is present in the transmembrane region of the protein and is away from the binding pocket of the protein. The residue Phe possesses an aromatic hydrophobic side chain and is capable of making stacking interactions with neighboring residues. On the other hand Leu is hydrophobic in nature but shorter and lacks the capability of forming stacking interactions. Since both the residues are hydrophobic, the overall conformation of wild-type and mutant is conserved. A minor variation is, however, observed in the region of mutation (residues 174--185) due to the alteration of interactions with the neighboring amino acid residue Arg177. Since the Phe residue possess a longer aromatic side chain, the Arg177 side chain shifts away from it to minimize steric hindrance and interacts with Ile164. The point mutation to the shorter residue Leu induces a conformational change in the Arg177 side chain orientation and positions it to interact with residue Trp163 ([Figure 5](#f5){ref-type="fig"}). This Phe181Leu mutation creates an empty space in this region leading to a decrease in hydrophobic interactions due to the shorter Leu and interruption of stacking capability in the mutant. Since this mutation lies in the transmembrane region, it will ultimately affect the capability of the CYB protein to interact with other interacting proteins.

![Model structure of wild-type human mitochondrial cytochrome b in cartoon rendering indicating secondary structure: helices (green), β-strand (red), and loop (orange). The side chain of Phe181 is shown as a ball and stick.](mv-v18-2687-f4){#f4}

![Model of wild-type human mitochondrial cytochrome b (green) superimposed on a model of F181L mutant (cyan). The side chain conformation of Phe181 and Arg177 (green) in the wild-type and Leu181 and Arg177 (cyan) in the mutant has been represented in the ball and stick. The conformation of the Arg177 side chain is different in the native and mutant protein. The Arg side chain in the wild-type adopts an orientation to minimize the repulsive force with Phe181.](mv-v18-2687-f5){#f5}

Moreover, energy calculations of the wild-type and mutated proteins \[[@r36]\] (Poisson Boltzman with nonpolar surface area) indicates that the wild-type model has slightly lower energy (−11416 kcal/mol) compared to the mutant model (−11351 kcal/mol), signifying it is more stable than the mutant. This further substantiates the reduction of the capability of Leu181 to form contacts with neighboring nonpolar residues compared to Phe181 in the wild-type protein.

Many mechanisms have been studied and proposed as the bases for the pathogenesis of mitochondrial optic neuropathies. Abnormalities in mtDNA have been associated with LHON, primary open angle glaucoma (POAG), pseudo exfoliation glaucoma (PEG), primary angle closure glaucoma (PACG), primary congenital glaucoma (PCG), and other spontaneous optic neuropathies \[[@r16],[@r31],[@r37]-[@r39]\]. It is generally agreed that there are two main sites in the respiratory chain where superoxide anions are generated, which are complex I and complex III \[[@r40],[@r41]\]. In the current study, complex I genes had 54% sequence changes. Neurons, because of their high energy requirement, are heavily dependent on mitochondria for survival \[[@r42]\]. Any malfunction of the mitochondrial electron transport chain results in excessive generation of free radicals and low ATP production. Oxidative stress (OS) has been suggested to play a crucial role in disease like glaucoma, LHON, proliferative vitreoretinopathies, and cataract \[[@r8],[@r38]\]. Pathogenic mitochondrial mutations can cause mitochondrial dysfunction and enhance OS, which in turn leads to apoptosis in affected tissue and primary culture of human cells that harbor mtDNA mutations \[[@r43]\]. Oxidative stress-induced mtDNA damage has also been reported in other diseases, such as premature ovarian insufficiency \[[@r44],[@r45]\], recurrent spontaneous abortions, and infertility \[[@r16],[@r45]\].

Nonsynonymous mitochondrial variations adversely affect oxidative phosphorylation resulting in decreased mitochondrial respiration and increased free radical production \[[@r46]\]. This study highlights the role of nonsynonymous mutations and its effects on mitochondrial protein structure. Larger studies are required to report other primary or secondary mutations. The effect of a particular mutation in mitochondrial disease depends on its threshold level in particular tissue. The type of mutation and penetrance also vary among haplogroups as certain alleles in particular haplogroups have protective or deleterious effects. The etiology of LHON is complex, but the pathology is rather focal for a mitochondrial disease as a vast majority of patients have only optic neuropathy. Thus, we emphasize that the mutation spectrum should be analyzed in a large number of cases and in different haplogroups. Knowledge of mtDNA mutations and mitochondrial dysfunction in LHON may lead to a better understanding of optic atrophy in LHON. Novel approaches are now available for studying mitochondrial disease in the eye, and a novel in vitro treatment has already been devised for the metabolic defect of at least one mtDNA mutation in LHON \[[@r47]\]. It is crucial that further work and ideas are forthcoming to realistically treat or prevent the transmission of mtDNA disease to future generations. No generally accepted measures have been shown to either prevent or delay the onset of blindness in LHON. The long-term management of visually impaired patients remains supportive, with provision of visual aids and registration with the relevant social services.
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